Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgenusAGEN -2.32%43 Interest Coverage is 0.74 as of Jun. 2026, which is 30% above its 10-year median of 0.57. GuruFocus rates AGEN with a GF Score™ of 43/100 and a GF Value™ of $3.78 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 373 Biotechnology companies, Agenus ranks worse than 97.86% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Agenus's
Operating Income
for the
three
months ended in Jun. 2026 was $11.3 Mil. Agenus's Interest Expense for the
three
months ended in Jun. 2026 was $-15.2 Mil.
Agenus's interest coverage for the quarter that ended in Jun. 2026 was 0.74.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Agenus Incs earnings cannot cover its interest expense. If the situation continues, the company may have to issue more debt.
The historical rank and industry rank for Agenus's Interest Coverage or its related term are showing as below:
AGEN'
s Interest Coverage Range Over the Past 10 Years
Min: 0.57 Med: 0.57 Max: 0.61
Current: 0.61
AGEN's Interest Coverage is ranked worse than 97.86% of 373
companies
in the Biotechnology industry
Industry Median: 99.7
vs AGEN: 0.61
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Agenus Interest Coverage Related Terms
Agenus Interest Coverage Historical Data
* Premium members only.
The historical data trend for Agenus's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
AGEN vs FULC, IRD, TTRX: Interest Coverage Comparison
For the Biotechnology subindustry, Agenus's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agenus's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Agenus's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agenus (AGEN) has a Interest Coverage of 0.74 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Agenus and its competitors. This is 30% above median its historical median of 0.57. Over the past decade, Agenus' Interest Coverage has ranged from 0.57 to 0.61. According to the industry distribution chart, Agenus ranks #365 out of 373 companies in the Biotechnology industry, placing it in the top 97.9%.
Is Agenus' Interest Coverage too high?
Agenus' current Interest Coverage of 0.74 is 30% above median its 10-year median of 0.57. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 0.61. The Biotechnology industry median Interest Coverage is 99.70. Agenus' value of 0.74 is 99.3% below this industry median. Based on the distribution chart, Agenus ranks #365 out of 373 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Agenus has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' Interest Coverage compare to FULC and IRD?
According to the Biotechnology industry distribution chart, Agenus ranks #365 out of 373 companies for Interest Coverage. This places Agenus in the lower half of its industry. The industry median Interest Coverage is 99.70. Agenus' value of 0.74 is 99.3% below this benchmark. Historically, Agenus' own Interest Coverage has ranged from 0.57 to 0.61 over the past decade. While the company's 10-year median is 0.57 vs. the industry median of 99.70, Agenus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 99.70, based on 373 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agenus's current Interest Coverage of 0.74 is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Agenus and its competitors. For the Biotechnology industry, the median Interest Coverage is 99.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agenus's current Interest Coverage is 0.74, which is 30% above median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (AGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.78, compared to a current price of $7.16 — trading 89.3% above its estimated fair value. The current Interest Coverage is 0.74, which is 30% above median its 10-year median of 0.57 and 99.3% below the Biotechnology industry median of 99.70. Agenus' overall GF Score™ is 43/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Agenus (AGEN), the current Interest Coverage is 0.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agenus (AGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Agenus stock appears to be overvalued.
The current stock price of $7.16 is trading 89.3% above its estimated GF Value™ of $3.78.
GuruFocus considers Agenus to be Significantly Overvalued.
Key valuation signals for AGEN:
Interest Coverage: 0.74 (30% above median its 10-year median of 0.57)
GF Value™: $3.78 vs. price of $7.16 (89.3% above fair value)
Industry Position: 99.3% below the Biotechnology median (#365 of 373)
No single metric tells the full story. See the AGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
43GF Score
Get the complete analysis for AGEN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGEN has been successfully added to your 
